Pneumologisches Studienzentrum München-West

At Pneumologisches Studienzentrum München-West, clinical trials focus on respiratory tract diseases with an emphasis on improving treatment options, symptom control, and long-term disease management across a range of chronic lung conditions.

• Studies in asthma, including severe and eosinophilic forms, are testing new therapies to reduce exacerbations and improve everyday breathing control.
• Chronic obstructive pulmonary disease research is evaluating approaches aimed at lowering flare-ups and supporting better long-term outcomes for people with persistent lung damage.
• Trials in cystic fibrosis are examining new treatments and supportive care options to improve safety, tolerability, and quality of life.
• Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis studies are exploring ways to preserve lung function and slow disease progression.
• Research on bronchiectasis and chronic cough is assessing novel therapies to reduce symptoms, lessen exacerbations, and improve respiratory comfort.

The site’s work reflects a strong interest in both established and emerging treatments, with many trials designed to test whether new medicines can improve control of chronic respiratory disease more effectively than current care.

This site conducts multiple studies in asthma, especially severe asthma and eosinophilic asthma, with a clear focus on reducing attacks, easing inflammation, and improving treatment response.

• Trials are evaluating new add-on therapies for people whose asthma remains uncontrolled despite standard inhaled treatment.
• Some studies compare emerging biologic and anti-inflammatory options with existing care to see whether they offer better protection against exacerbations.
• Research also includes testing whether new inhaled formulations can improve safety, tolerability, and overall asthma control.

These studies aim to give patients with difficult-to-control asthma more effective options and help clinicians better tailor treatment to disease severity and inflammatory profile.

Clinical research in chronic obstructive pulmonary disease at this Munich site centers on reducing exacerbations, improving daily breathing, and evaluating treatments for people with ongoing symptoms despite standard therapy.

• Several trials are testing new add-on therapies for patients with frequent flare-ups and a history of worsening disease.
• Studies also explore whether targeted treatments can help people with COPD linked to type 2 inflammation or former smoking.
• Related research includes chronic bronchitis and broader COPD symptom control, with the goal of improving long-term disease stability.

Overall, the work in this area is aimed at finding better ways to prevent exacerbations and support more stable lung function over time.

The site also has active research in cystic fibrosis, including studies of therapies intended to improve respiratory outcomes and support patients who also live with pancreatic exocrine insufficiency.

• Some trials are assessing new combination treatments to improve long-term safety and tolerability in people with cystic fibrosis.
• Other studies are looking at inhaled or supportive therapies that may help manage symptoms and overall disease burden.
• Patient acceptability research is included as well, showing interest in making treatment easier to use in everyday life.

This research reflects a broader effort to improve both disease control and treatment experience for people living with a complex, lifelong condition.

Another major focus is fibrotic lung disease, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, alongside studies in bronchiectasis.

• Trials in fibrotic disease are examining whether new therapies can help preserve lung function and slow worsening of scarring in the lungs.
• Research in bronchiectasis is testing treatments designed to reduce pulmonary exacerbations and improve symptom burden.
• These studies are especially relevant for patients with chronic cough, recurrent infections, and ongoing breathing difficulties.

By addressing both fibrosis and airway damage, the Pneumologisches Studienzentrum München-West contributes to research that may expand options for people with few established treatment choices.

The site is also involved in trials for refractory chronic cough and unexplained chronic cough, where the main goal is to better understand and relieve persistent cough that does not improve with standard care.

• These studies are evaluating new therapies intended to reduce cough frequency and improve day-to-day comfort.
• Research in this area also looks at safety and tolerability, which is important for patients who may need longer-term symptom management.
• Some work includes related airway inflammation measures to help guide future treatment development.

This reflects a growing interest in treating chronic cough as a distinct clinical problem rather than only a symptom of other lung diseases.